In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor of medicine at Northwestern University, discusses the phase 2 TRANSCEND FL study presented at SOHO 2025 titled, “Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL).”
In the TRANSCEND FL study, liso-cel showed deep and durable responses and had a manageable safety profile, according to the authors.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
